Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

NEW YORK, April 5, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer, will present at the MicroCap Conference being held at the Essex House in New York...

Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

NEW YORK, March 16, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a...

Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA

NEW YORK, March 9, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer will present at the 30th Annual Roth Conference, being held at the Ritz Carlton in Dana...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

 

 

CONTACT

501 Madison Ave, 14th Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com